Kymera in the News
Read about breakthroughs, clinical advancements, and ongoing work to develop new medicines at Kymera.
Featured Perspectives
Watertown News: Prospective Young Scientists Get a Look at a Real Lab at Watertown’s Kymera Therapeutics
A group of aspiring young scientists got a glimpse inside a Watertown company that does cutting-edge biopharmaceutical research.
BiotechTV: Kymera shows us the technologies that enable the development of protein degradation based medicines
Nello Mainolfi explains the concept of protein degradation and describes three key technologies that enable precision protein measurement
PharmaVoice: A pharma summer — how leaders unwind and recharge their teams in the warmer months
With more attention being paid to work-life balance and employee burnout, a slower summer may not be a bad thing. The biopharma industry in particular is often go-go-go, but industry leaders still look for ways to stop and smell the roses while keeping innovation on track.
BioSpace: First Protein Degrader Tested Outside Oncology Yields Promising Results
Kymera and Sanofi shared positive results for an IRAK4 degrader for hidradenitis suppurativa (HS) and atopic dermatitis (AD), breaking ground to take protein degradation outside the field of oncology and into inflammatory disease indications.
BioPharma Dive: Kymera shares jump on Sanofi’s decision to advance protein-degrading drug
Sanofi will advance an experimental inflammatory disease drug into Phase 2 clinical testing after its biotechnology company partner Kymera Therapeutics reported Wednesday what it described as encouraging results from a small study.
Nasdaq: Kymera (KYMR) Up on Positive Data From Phase I Study on KT-474
KYMR announced positive clinical data from a phase I study evaluating its highly selective, orally bioavailable IRAK4 degrader, KT-474, for the treatment of patients with hidradenitis suppurativa (“HS”) and atopic dermatitis (“AD”).
Fierce Biotech: Sanofi takes inflammatory disease protein degrader forward as Kymera shares glimpse of efficacy
Kymera Therapeutics has generated the first early clinical evidence that its targeted protein degradation technology works in immune-inflammatory diseases.
Endpoints News: Kymera and Sanofi move ahead with skin drug after promising PhI data
Kymera and Sanofi plan to move ahead with the skin drug that the French drugmaker paid $150 million in cash in 2020 to partner on, after positive Phase I results on the IRAK4 degrader they’ve been working on for a pair of skin conditions.
Boston Globe: Top Places to Work in Massachusetts 2022
Kymera’s wellness stipend, instituted at the beginning of the year, is designed to let workers know “we care about them, and want to give them a way to care for themselves,” says Karen Weisbach, vice president of people and culture.
PharmaVoice: The 2022 PharmaVoice 100 – Nello Mainolfi
Nello Mainolfi, co-founder, president and CEO of Kymera Therapeutics, has an empty prescription bottle on his desk — a bottle that he hopes to soon fill with with one of the biotech company’s drugs.